Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response.

ABSTRACT:

Introduction

Phase 3 trial of 6-month subcutaneous leuprolide acetate (SC-LA) in children with central precocious puberty (CPP) demonstrated efficacy and safety. The aims of this secondary analysis were to evaluate unstimulated luteinizing hormone (LH) as efficacy measure, assess clinical suppression metrics, and present biochemical and clinical data for subgroups not achieving hormone suppression.

Methods

Sixty-two children with treatment-naïve CPP received 2 doses of 45 mg SC-LA at 24-week intervals. Unstimulated and GnRH-stimulated LH, E₂, and T concentrations were measured. Clinical measures included bone age (BA) and predicted adult height (PAH).

Results

Eighty-four percentage and 86% of children achieved unstimulated LH <1 IU/L at weeks 24 and 48, res

SUBMITTER: Klein K 

PROVIDER: S-EPMC12416875 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature